Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

It Takes Change to Make Change: Good Publication Practice-Image Handling.

Lahortiga I, Cox L.

Hemasphere. 2017 Dec 20;1(1):e6. doi: 10.1097/HS9.0000000000000006. eCollection 2017 Dec. No abstract available.

2.

Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling.

Wandinger SK, Lahortiga I, Jacobs K, Klammer M, Jordan N, Elschenbroich S, Parade M, Jacoby E, Linders JT, Brehmer D, Cools J, Daub H.

PLoS One. 2016 Jan 8;11(1):e0146100. doi: 10.1371/journal.pone.0146100. eCollection 2016.

3.

Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia.

Vicente C, Schwab C, Broux M, Geerdens E, Degryse S, Demeyer S, Lahortiga I, Elliott A, Chilton L, La Starza R, Mecucci C, Vandenberghe P, Goulden N, Vora A, Moorman AV, Soulier J, Harrison CJ, Clappier E, Cools J.

Haematologica. 2015 Oct;100(10):1301-10. doi: 10.3324/haematol.2015.130179. Epub 2015 Jul 23.

4.

Hedgehog pathway mutations in T-cell acute lymphoblastic leukemia.

Dagklis A, Pauwels D, Lahortiga I, Geerdens E, Bittoun E, Cauwelier B, Tousseyn T, Uyttebroeck A, Maertens J, Verhoef G, Vandenberghe P, Cools J.

Haematologica. 2015 Mar;100(3):e102-5. doi: 10.3324/haematol.2014.119248. Epub 2014 Dec 19. No abstract available.

5.

CD74-NRG1 fusions in lung adenocarcinoma.

Fernandez-Cuesta L, Plenker D, Osada H, Sun R, Menon R, Leenders F, Ortiz-Cuaran S, Peifer M, Bos M, Daßler J, Malchers F, Schöttle J, Vogel W, Dahmen I, Koker M, Ullrich RT, Wright GM, Russell PA, Wainer Z, Solomon B, Brambilla E, Nagy-Mignotte H, Moro-Sibilot D, Brambilla CG, Lantuejoul S, Altmüller J, Becker C, Nürnberg P, Heuckmann JM, Stoelben E, Petersen I, Clement JH, Sänger J, Muscarella LA, la Torre A, Fazio VM, Lahortiga I, Perera T, Ogata S, Parade M, Brehmer D, Vingron M, Heukamp LC, Buettner R, Zander T, Wolf J, Perner S, Ansén S, Haas SA, Yatabe Y, Thomas RK.

Cancer Discov. 2014 Apr;4(4):415-22. doi: 10.1158/2159-8290.CD-13-0633. Epub 2014 Jan 27.

6.

Identification of novel FLT3 kinase inhibitors.

Pauwels D, Klaassen H, Lahortiga I, Kilonda A, Jacobs K, Sweron B, Corbau R, Chaltin P, Marchand A, Cools J.

Eur J Med Chem. 2013 May;63:713-21. doi: 10.1016/j.ejmech.2013.03.024. Epub 2013 Mar 21.

PMID:
23567961
7.

Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia.

De Keersmaecker K, Atak ZK, Li N, Vicente C, Patchett S, Girardi T, Gianfelici V, Geerdens E, Clappier E, Porcu M, Lahortiga I, Lucà R, Yan J, Hulselmans G, Vranckx H, Vandepoel R, Sweron B, Jacobs K, Mentens N, Wlodarska I, Cauwelier B, Cloos J, Soulier J, Uyttebroeck A, Bagni C, Hassan BA, Vandenberghe P, Johnson AW, Aerts S, Cools J.

Nat Genet. 2013 Feb;45(2):186-90. doi: 10.1038/ng.2508. Epub 2012 Dec 23.

8.

Chromosomal aberrations and fusion genes in myeloid malignancies.

Gianfelici V, Lahortiga I, Cools J.

Expert Rev Hematol. 2012 Aug;5(4):381-93. Review.

PMID:
22992233
9.

High accuracy mutation detection in leukemia on a selected panel of cancer genes.

Kalender Atak Z, De Keersmaecker K, Gianfelici V, Geerdens E, Vandepoel R, Pauwels D, Porcu M, Lahortiga I, Brys V, Dirks WG, Quentmeier H, Cloos J, Cuppens H, Uyttebroeck A, Vandenberghe P, Cools J, Aerts S.

PLoS One. 2012;7(6):e38463. doi: 10.1371/journal.pone.0038463. Epub 2012 Jun 4.

10.

New opportunities and new problems for acute myeloid leukemia treatment.

Lahortiga I, Cools J.

Haematologica. 2012 Jun;97(6):796. doi: 10.3324/haematol.2012.070243. No abstract available.

11.

Overexpression of GATA2 predicts an adverse prognosis for patients with acute myeloid leukemia and it is associated with distinct molecular abnormalities.

Vicente C, Vazquez I, Conchillo A, García-Sánchez MA, Marcotegui N, Fuster O, González M, Calasanz MJ, Lahortiga I, Odero MD.

Leukemia. 2012 Mar;26(3):550-4. doi: 10.1038/leu.2011.235. Epub 2011 Sep 9. No abstract available.

PMID:
21904383
12.

Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia.

Vázquez I, Maicas M, Cervera J, Agirre X, Marin-Béjar O, Marcotegui N, Vicente C, Lahortiga I, Gomez-Benito M, Carranza C, Valencia A, Brunet S, Lumbreras E, Prosper F, Gómez-Casares MT, Hernández-Rivas JM, Calasanz MJ, Sanz MA, Sierra J, Odero MD.

Haematologica. 2011 Oct;96(10):1448-56. doi: 10.3324/haematol.2011.040535. Epub 2011 Jul 12.

13.

JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma.

Van Roosbroeck K, Cox L, Tousseyn T, Lahortiga I, Gielen O, Cauwelier B, De Paepe P, Verhoef G, Marynen P, Vandenberghe P, De Wolf-Peeters C, Cools J, Wlodarska I.

Blood. 2011 Apr 14;117(15):4056-64. doi: 10.1182/blood-2010-06-291310. Epub 2011 Feb 15.

PMID:
21325169
14.

Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia.

Kleppe M, Lahortiga I, El Chaar T, De Keersmaecker K, Mentens N, Graux C, Van Roosbroeck K, Ferrando AA, Langerak AW, Meijerink JP, Sigaux F, Haferlach T, Wlodarska I, Vandenberghe P, Soulier J, Cools J.

Nat Genet. 2010 Jun;42(6):530-5. doi: 10.1038/ng.587. Epub 2010 May 16.

15.

Spectral karyotyping (SKY).

Belloni E, Lahortiga I, Odero M, Di Fiore P, Pelicci P.

Ecancermedicalscience. 2010;4:181. doi: 10.3332/ecancer.2010.181. Epub 2010 Oct 13. No abstract available. Erratum in: Ecancermedicalscience. 2012;6:256. Bonnomi, E [removed].

16.

Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia.

Graux C, Stevens-Kroef M, Lafage M, Dastugue N, Harrison CJ, Mugneret F, Bahloula K, Struski S, Grégoire MJ, Nadal N, Lippert E, Taviaux S, Simons A, Kuiper RP, Moorman AV, Barber K, Bosly A, Michaux L, Vandenberghe P, Lahortiga I, De Keersmaecker K, Wlodarska I, Cools J, Hagemeijer A, Poirel HA; Groupe Francophone de Cytogénétique Hématologique; Belgian Cytogenetic Group for Hematology and Oncology.

Leukemia. 2009 Jan;23(1):125-33. doi: 10.1038/leu.2008.278. Epub 2008 Oct 16.

PMID:
18923437
17.

In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.

De Keersmaecker K, Lahortiga I, Mentens N, Folens C, Van Neste L, Bekaert S, Vandenberghe P, Odero MD, Marynen P, Cools J.

Haematologica. 2008 Apr;93(4):533-42. doi: 10.3324/haematol.11894. Epub 2008 Mar 5.

18.

Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion.

Lahortiga I, Akin C, Cools J, Wilson TM, Mentens N, Arthur DC, Maric I, Noel P, Kocabas C, Marynen P, Lessin LS, Wlodarska I, Robyn J, Metcalfe DD.

Haematologica. 2008 Jan;93(1):49-56. doi: 10.3324/haematol.11836.

19.

Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice.

Shing DC, Trubia M, Marchesi F, Radaelli E, Belloni E, Tapinassi C, Scanziani E, Mecucci C, Crescenzi B, Lahortiga I, Odero MD, Zardo G, Gruszka A, Minucci S, Di Fiore PP, Pelicci PG.

J Clin Invest. 2007 Dec;117(12):3696-707.

20.

JAK2-V617F activating mutation in acute myeloid leukemia: prognostic impact and association with other molecular markers.

Vicente C, Vázquez I, Marcotegui N, Conchillo A, Carranza C, Rivell G, Bandrés E, Cristobal I, Lahortiga I, Calasanz MJ, Odero MD.

Leukemia. 2007 Nov;21(11):2386-90. Epub 2007 Jun 21. No abstract available. Erratum in: Leukemia. 2007 Dec;21(12):2576.

PMID:
17581610
21.

Simultaneous translocations of FGFR3/MMSET and CCND1 into two different IGH alleles in multiple myeloma: lack of concurrent activation of both proto-oncogenes.

Sáez B, Martín-Subero JI, Lahortiga I, Largo C, Larrayoz MJ, Odero MD, Prosper F, Cigudosa JC, Siebert R, Calasanz MJ.

Cancer Genet Cytogenet. 2007 May;175(1):65-8.

PMID:
17498561
22.

Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia.

Lahortiga I, De Keersmaecker K, Van Vlierberghe P, Graux C, Cauwelier B, Lambert F, Mentens N, Beverloo HB, Pieters R, Speleman F, Odero MD, Bauters M, Froyen G, Marynen P, Vandenberghe P, Wlodarska I, Meijerink JP, Cools J.

Nat Genet. 2007 May;39(5):593-5. Epub 2007 Apr 15.

PMID:
17435759
23.

The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.

Lierman E, Lahortiga I, Van Miegroet H, Mentens N, Marynen P, Cools J.

Haematologica. 2007 Jan;92(1):27-34.

24.

A novel t(2;3)(p11;q27) in a case of follicular lymphoma.

Tapinassi C, Micucci C, Lahortiga I, Malazzi O, Gasparini P, Gorosquieta A, Odero MD, Belloni E.

Cancer Genet Cytogenet. 2007 Jan 1;172(1):70-3.

PMID:
17175383
25.

Transition from EML1-ABL1 to NUP214-ABL1 positivity in a patient with acute T-lymphoblastic leukemia.

De Keersmaecker K, Lahortiga I, Graux C, Marynen P, Maertens J, Cools J, Vandenberghe P.

Leukemia. 2006 Dec;20(12):2202-4. Epub 2006 Oct 5. No abstract available.

PMID:
17024111
26.

Geographic differences in the incidence of cytogenetic abnormalities of acute myelogenous leukemia (AML) in Spain.

Sierra M, Alonso A, Odero MD, Gonzalez MB, Lahortiga I, Pérez JJ, García JL, Gutiérrez NC, Calasanz MJ, San Miguel JF, Hernández JM.

Leuk Res. 2006 Aug;30(8):943-8. Epub 2006 Feb 28.

PMID:
16503352
27.

Cryptic chromosomal aberrations waiting to be discovered.

Lahortiga I, Cools J.

Leukemia. 2006 Feb;20(2):210-1. No abstract available.

PMID:
16357829
28.

Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia.

Agirre X, Román-Gómez J, Vázquez I, Jiménez-Velasco A, Garate L, Montiel-Duarte C, Artieda P, Cordeu L, Lahortiga I, Calasanz MJ, Heiniger A, Torres A, Minna JD, Prósper F.

Int J Cancer. 2006 Apr 15;118(8):1945-53.

29.

Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib.

Agirre X, Román-Gómez J, Vázquez I, Jiménez-Velasco A, Larráyoz MJ, Lahortiga I, Andreu EJ, Márquez J, Beltrán de Heredia JM, Odero MD, Prósper F, Calasanz MJ.

Cancer Genet Cytogenet. 2005 Jul 1;160(1):22-6.

30.

FISH analysis of hematological neoplasias with 1p36 rearrangements allows the definition of a cluster of 2.5 Mb included in the minimal region deleted in 1p36 deletion syndrome.

Lahortiga I, Vázquez I, Belloni E, Román JP, Gasparini P, Novo FJ, Zudaire I, Pelicci PG, Hernández JM, Calasanz MJ, Odero MD.

Hum Genet. 2005 May;116(6):476-85. Epub 2005 Mar 3.

31.

NUP98 is fused to HOXA9 in a variant complex t(7;11;13;17) in a patient with AML-M2.

Lahortiga I, Belloni E, Vázquez I, Agirre X, Larrayoz MJ, Vizmanos JL, Valgañón M, Zudaire I, Sáez B, Mateos MC, Di Fiore PP, Calasanz MJ, Odero MD.

Cancer Genet Cytogenet. 2005 Mar;157(2):151-6. Erratum in: Cancer Genet Cytogenet. 2005 Jun;159(2):194.

32.

Cryptic ins(2;11) with clonal evolution showing amplification of 11q23-q25 either on hsr(11) or on dmin, in a patient with AML-M2.

Vazquez I, Lahortiga I, Agirre X, Larrayoz MJ, Vizmanos JL, Ardanaz MT, Zeleznik-Le NJ, Calasanz MJ, Odero MD.

Leukemia. 2004 Dec;18(12):2041-4. No abstract available.

PMID:
15483676
33.

A new complex rearrangement involving the ETV6, LOC115548, and MN1 genes in a case of acute myeloid leukemia.

Belloni E, Trubia M, Mancini M, Derme V, Nanni M, Lahortiga I, Riccioni R, Confalonieri S, Lo-Coco F, Di Fiore PP, Pelicci PG.

Genes Chromosomes Cancer. 2004 Nov;41(3):272-7.

PMID:
15334551
34.

Remission of acute monocytic leukemia, secondary to treatment with epipodophyllotoxins, in a patient with t(8;16)(p11;p13) and MYST3-CREBBP fusion.

Vizmanos JL, Larráyoz MJ, Vázquez I, Odero MD, Hernández R, Lahortiga I, Novo FJ, Ardanaz MT, Calasanz MJ.

Cancer Genet Cytogenet. 2004 Jul 15;152(2):177-8. No abstract available.

PMID:
15262444
35.

Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements.

Lahortiga I, Vázquez I, Agirre X, Larrayoz MJ, Vizmanos JL, Gozzetti A, Calasanz MJ, Odero MD.

Genes Chromosomes Cancer. 2004 Jul;40(3):179-89.

36.

NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder.

Vizmanos JL, Novo FJ, Román JP, Baxter EJ, Lahortiga I, Larráyoz MJ, Odero MD, Giraldo P, Calasanz MJ, Cross NC.

Cancer Res. 2004 Apr 15;64(8):2673-6.

37.

Molecular characterization of a t(1;3)(p36;q21) in a patient with MDS. MEL1 is widely expressed in normal tissues, including bone marrow, and it is not overexpressed in the t(1;3) cells.

Lahortiga I, Agirre X, Belloni E, Vázquez I, Larrayoz MJ, Gasparini P, Lo Coco F, Pelicci PG, Calasanz MJ, Odero MD.

Oncogene. 2004 Jan 8;23(1):311-6.

38.

TP53 is frequently altered by methylation, mutation, and/or deletion in acute lymphoblastic leukaemia.

Agirre X, Novo FJ, Calasanz MJ, Larráyoz MJ, Lahortiga I, Valgañón M, García-Delgado M, Vizmanos JL.

Mol Carcinog. 2003 Dec;38(4):201-8.

PMID:
14639659
39.

NUP98 is fused to adducin 3 in a patient with T-cell acute lymphoblastic leukemia and myeloid markers, with a new translocation t(10;11)(q25;p15).

Lahortiga I, Vizmanos JL, Agirre X, Vázquez I, Cigudosa JC, Larrayoz MJ, Sala F, Gorosquieta A, Perez-Equiza K, Calasanz MJ, Odero MD.

Cancer Res. 2003 Jun 15;63(12):3079-83.

40.

Molecular cytogenetic characterization of breakpoints in 19 patients with hematologic malignancies and 12p unbalanced translocations.

Odero MD, Carlson K, Lahortiga I, Calasanz MJ, Rowley JD.

Cancer Genet Cytogenet. 2003 Apr 15;142(2):115-9.

41.

t(10;16)(q22;p13) and MORF-CREBBP fusion is a recurrent event in acute myeloid leukemia.

Vizmanos JL, Larráyoz MJ, Lahortiga I, Floristán F, Alvarez C, Odero MD, Novo FJ, Calasanz MJ.

Genes Chromosomes Cancer. 2003 Apr;36(4):402-5.

42.

Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders.

Baxter EJ, Kulkarni S, Vizmanos JL, Jaju R, Martinelli G, Testoni N, Hughes G, Salamanchuk Z, Calasanz MJ, Lahortiga I, Pocock CF, Dang R, Fidler C, Wainscoat JS, Boultwood J, Cross NC.

Br J Haematol. 2003 Jan;120(2):251-6.

PMID:
12542482
43.

A novel gene, MDS2, is fused to ETV6/TEL in a t(1;12)(p36.1;p13) in a patient with myelodysplastic syndrome.

Odero MD, Vizmanos JL, Román JP, Lahortiga I, Panizo C, Calasanz MJ, Zeleznik-Le NJ, Rowley JD, Novo FJ.

Genes Chromosomes Cancer. 2002 Sep;35(1):11-9.

44.

Insertion (22;9)(q11;q34q21) in a patient with chronic myeloid leukemia characterized by fluorescence in situ hybridization.

Martín-Subero JI, Lahortiga I, Gómez E, Ferreira C, Larrayoz MJ, Odero MD, García-Delgado M, Novo FJ, Giraldo P, Calasanz MJ.

Cancer Genet Cytogenet. 2001 Mar;125(2):167-70.

45.

Identification of new translocations involving ETV6 in hematologic malignancies by fluorescence in situ hybridization and spectral karyotyping.

Odero MD, Carlson K, Calasanz MJ, Lahortiga I, Chinwalla V, Rowley JD.

Genes Chromosomes Cancer. 2001 Jun;31(2):134-42.

Supplemental Content

Loading ...
Support Center